← Back to feedRead original →
VERIFIEDET Finance·neutral
Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar
AI Summary
- ·Cipla's US unit has partnered with China's Qilu Pharmaceutical for a Keytruda biosimilar.
- ·Qilu will manage development, approvals, manufacturing, and supply of the biosimilar.
- ·Cipla USA will be responsible for commercializing the treatment in the US market.